Recent News

• 02.12.2026 - BioRestorative Announces Pricing of $5.0 Million Public Offering
• 02.11.2026 - BioRestorative Announces Positive Outcome from Type B Meeting with FDA
• 02.10.2026 - BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
• 11.17.2025 - BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
• 11.12.2025 - BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.12.2025 - BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.05.2025 - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
• 11.05.2025 - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
• 10.27.2025 - BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Recent Filings

• 02.10.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.09.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.19.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.19.2025 - DRS Draft Registration Statement
• 12.12.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.10.2025 - EFFECT Notice of Effectiveness
• 11.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.18.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]